Dual effects of cyclooxygenase inhibitors in combination with CD19.CAR-T cell immunotherapy
CAR-T cells targeting CD19 came into clinical practice for the treatment of B cell lymphoma in 2018. However, patients being treated for B cell lymphoma often suffer from comorbidities such as chronic pain, cardiovascular diseases and arthritis. Thus, these patients frequently receive concomitant me...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
26 May 2021
|
| In: |
Frontiers in immunology
Year: 2021, Jahrgang: 12 |
| ISSN: | 1664-3224 |
| DOI: | 10.3389/fimmu.2021.670088 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fimmu.2021.670088 Verlag, kostenfrei, Volltext: https://www.frontiersin.org/articles/10.3389/fimmu.2021.670088/full 
|
| Verfasserangaben: | Mingya Yang, Lei Wang, Ming Ni, Brigitte Neuber, Sanmei Wang, Wenjie Gong, Tim Sauer, Maria-Luisa Schubert, Angela Hückelhoven-Krauss, Ruixiang Xia, Jian Ge, Christian Kleist, Volker Eckstein, Leopold Sellner, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt and Anita Schmitt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1761975218 | ||
| 003 | DE-627 | ||
| 005 | 20230426093913.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210706s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2021.670088 |2 doi | |
| 035 | |a (DE-627)1761975218 | ||
| 035 | |a (DE-599)KXP1761975218 | ||
| 035 | |a (OCoLC)1264431711 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Yang, Mingya |d 1989- |e VerfasserIn |0 (DE-588)117476788X |0 (DE-627)1045595365 |0 (DE-576)51592282X |4 aut | |
| 245 | 1 | 0 | |a Dual effects of cyclooxygenase inhibitors in combination with CD19.CAR-T cell immunotherapy |c Mingya Yang, Lei Wang, Ming Ni, Brigitte Neuber, Sanmei Wang, Wenjie Gong, Tim Sauer, Maria-Luisa Schubert, Angela Hückelhoven-Krauss, Ruixiang Xia, Jian Ge, Christian Kleist, Volker Eckstein, Leopold Sellner, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt and Anita Schmitt |
| 264 | 1 | |c 26 May 2021 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 06.07.2021 | ||
| 520 | |a CAR-T cells targeting CD19 came into clinical practice for the treatment of B cell lymphoma in 2018. However, patients being treated for B cell lymphoma often suffer from comorbidities such as chronic pain, cardiovascular diseases and arthritis. Thus, these patients frequently receive concomitant medications that include NSAIDs like COX inhibitors. Celecoxib, a selective COX-2 inhibitor, and aspirin, a non-selective COX-1 and COX-2 inhibitor, are being used as anti-inflammatory, analgesic and anti-pyretic drugs. In addition, several studies have also focused on the anti-neoplastic properties of COX-inhibitors. As the influence of COX-inhibitors on CD19.CAR-T cells is still unknown, we investigated the effect of celecoxib and aspirin on the quantity and quality of CD19.CAR-T cells at different concentrations with special regard to cytotoxicity, activation, cytokine release, proliferation and exhaustion. A significant effect on CAR-T cells could be observed for 0.1 mmol/L of celecoxib and for 4 mmol/L of aspirin. At these concentrations, we found that both COX-inhibitors could induce intrinsic apoptosis of CD19.CAR-T cells showing a significant reduction in the ratio of JC-10red to JC-10green CAR-T cells from 6.46 ± 7.03 to 1.76 ± 0.67 by celecoxib and to 4.41 ± 0.32 by aspirin, respectively. Additionally, the ratios of JC-10red to JC-10green Daudi cells were also decreased from 3.41 ± 0.30 to 0.77 ± 0.06 by celecoxib and to 1.26 ± 0.04 by aspirin, respectively. Although the cytokine release by CD19.CAR-T cells upon activation was not hampered by both COX-inhibitors, activation and proliferation of CAR-T cells were significantly inhibited via diminishing the NF-ĸB signaling pathway by a significant down-regulation (about 45%) of expression of CD27 on CD4+/CD8+ CAR-T cells, followed by a clear decrease of phosphorylated NF-ĸB p65 in both CD4+/CD8+ CAR-T cells by a factor of 1.8. Of note, COX-inhibitors hampered expansion and induced exhaustion of CAR-T cells in an antigen stress assay. Collectively, our findings indicate that the use of COX-inhibitors is a double-edged sword that not only induces apoptosis in tumor cells but also impairs the quantity and quality of CAR-T cells. Therefore, COX-inhibitors should be used with caution in patients with B cell lymphoma under CAR-T cell therapy. | ||
| 650 | 4 | |a Acetylsalycilic acid | |
| 650 | 4 | |a CD19.CAR-T cells | |
| 650 | 4 | |a Celecoxib | |
| 650 | 4 | |a inhibitors | |
| 650 | 4 | |a NSAIDs | |
| 650 | 4 | |a Persistence | |
| 700 | 1 | |a Wang, Lei |d 1985- |e VerfasserIn |0 (DE-588)1076031994 |0 (DE-627)834093308 |0 (DE-576)444802398 |4 aut | |
| 700 | 1 | |a Neuber, Brigitte |d 1974- |e VerfasserIn |0 (DE-588)1052913563 |0 (DE-627)789293188 |0 (DE-576)408653884 |4 aut | |
| 700 | 1 | |a Wang, Sanmei |d 1990- |e VerfasserIn |0 (DE-588)1191709442 |0 (DE-627)1670170527 |4 aut | |
| 700 | 1 | |a Sauer, Tim |d 1981- |e VerfasserIn |0 (DE-588)138282013 |0 (DE-627)601099516 |0 (DE-576)307058166 |4 aut | |
| 700 | 1 | |a Schubert, Maria-Luisa |d 1982- |e VerfasserIn |0 (DE-588)1147867631 |0 (DE-627)1007273801 |0 (DE-576)49608089X |4 aut | |
| 700 | 1 | |a Hückelhoven-Krauss, Angela |d 1983- |e VerfasserIn |0 (DE-588)1034095889 |0 (DE-627)744057280 |0 (DE-576)381742822 |4 aut | |
| 700 | 1 | |a Kleist, Christian |e VerfasserIn |0 (DE-588)138977410 |0 (DE-627)703170287 |0 (DE-576)309272971 |4 aut | |
| 700 | 1 | |a Eckstein, Volker |d 1957- |e VerfasserIn |0 (DE-588)172851408 |0 (DE-627)697780732 |0 (DE-576)133707059 |4 aut | |
| 700 | 1 | |a Sellner, Leopold |d 1984- |e VerfasserIn |0 (DE-588)143493825 |0 (DE-627)646576704 |0 (DE-576)337362963 |4 aut | |
| 700 | 1 | |a Müller-Tidow, Carsten |d 1968- |e VerfasserIn |0 (DE-588)1015101798 |0 (DE-627)705330230 |0 (DE-576)351197893 |4 aut | |
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 700 | 1 | |a Schmitt, Michael |d 1966- |e VerfasserIn |0 (DE-588)133177173 |0 (DE-627)538000600 |0 (DE-576)299672921 |4 aut | |
| 700 | 1 | |a Schmitt, Anita |d 1969- |e VerfasserIn |0 (DE-588)141722495 |0 (DE-627)630587752 |0 (DE-576)325593892 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d Lausanne : Frontiers Media, 2010 |g 12(2021) vom: 26. Mai, Artikel-ID 670088 |h Online-Ressource |w (DE-627)657998354 |w (DE-600)2606827-8 |w (DE-576)343624834 |x 1664-3224 |7 nnas |a Dual effects of cyclooxygenase inhibitors in combination with CD19.CAR-T cell immunotherapy |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g day:26 |g month:05 |g elocationid:670088 |g extent:13 |a Dual effects of cyclooxygenase inhibitors in combination with CD19.CAR-T cell immunotherapy |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fimmu.2021.670088 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fimmu.2021.670088/full |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210706 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 141722495 |a Schmitt, Anita |m 141722495:Schmitt, Anita |d 910000 |d 910100 |d 50000 |e 910000PS141722495 |e 910100PS141722495 |e 50000PS141722495 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 18 |y j | ||
| 998 | |g 133177173 |a Schmitt, Michael |m 133177173:Schmitt, Michael |d 910000 |d 910100 |e 910000PS133177173 |e 910100PS133177173 |k 0/910000/ |k 1/910000/910100/ |p 17 | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 16 | ||
| 998 | |g 1015101798 |a Müller-Tidow, Carsten |m 1015101798:Müller-Tidow, Carsten |d 910000 |d 910100 |e 910000PM1015101798 |e 910100PM1015101798 |k 0/910000/ |k 1/910000/910100/ |p 15 | ||
| 998 | |g 143493825 |a Sellner, Leopold |m 143493825:Sellner, Leopold |d 50000 |e 50000PS143493825 |k 0/50000/ |p 14 | ||
| 998 | |g 172851408 |a Eckstein, Volker |m 172851408:Eckstein, Volker |d 910000 |d 910100 |e 910000PE172851408 |e 910100PE172851408 |k 0/910000/ |k 1/910000/910100/ |p 13 | ||
| 998 | |g 138977410 |a Kleist, Christian |m 138977410:Kleist, Christian |d 910000 |d 911400 |e 910000PK138977410 |e 911400PK138977410 |k 0/910000/ |k 1/910000/911400/ |p 12 | ||
| 998 | |g 143493825 |a Sellner, Leopold |m 143493825:Sellner, Leopold |d 50000 |e 50000PS143493825 |k 0/50000/ |p 10 | ||
| 998 | |g 1034095889 |a Hückelhoven-Krauss, Angela |m 1034095889:Hückelhoven-Krauss, Angela |d 910000 |d 910100 |e 910000PH1034095889 |e 910100PH1034095889 |k 0/910000/ |k 1/910000/910100/ |p 9 | ||
| 998 | |g 1147867631 |a Schubert, Maria-Luisa |m 1147867631:Schubert, Maria-Luisa |d 910000 |d 910100 |e 910000PS1147867631 |e 910100PS1147867631 |k 0/910000/ |k 1/910000/910100/ |p 8 | ||
| 998 | |g 138282013 |a Sauer, Tim |m 138282013:Sauer, Tim |d 910000 |d 910100 |e 910000PS138282013 |e 910100PS138282013 |k 0/910000/ |k 1/910000/910100/ |p 7 | ||
| 998 | |g 1191709442 |a Wang, Sanmei |m 1191709442:Wang, Sanmei |p 5 | ||
| 998 | |g 1052913563 |a Neuber, Brigitte |m 1052913563:Neuber, Brigitte |d 910000 |d 910100 |e 910000PN1052913563 |e 910100PN1052913563 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 1076031994 |a Wang, Lei |m 1076031994:Wang, Lei |p 2 | ||
| 998 | |g 117476788X |a Yang, Mingya |m 117476788X:Yang, Mingya |d 910000 |d 910100 |e 910000PY117476788X |e 910100PY117476788X |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1761975218 |e 3945729998 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"title":[{"title_sort":"Dual effects of cyclooxygenase inhibitors in combination with CD19.CAR-T cell immunotherapy","title":"Dual effects of cyclooxygenase inhibitors in combination with CD19.CAR-T cell immunotherapy"}],"person":[{"given":"Mingya","display":"Yang, Mingya","family":"Yang","role":"aut"},{"role":"aut","family":"Wang","display":"Wang, Lei","given":"Lei"},{"display":"Neuber, Brigitte","given":"Brigitte","family":"Neuber","role":"aut"},{"role":"aut","family":"Wang","given":"Sanmei","display":"Wang, Sanmei"},{"family":"Sauer","display":"Sauer, Tim","given":"Tim","role":"aut"},{"role":"aut","family":"Schubert","display":"Schubert, Maria-Luisa","given":"Maria-Luisa"},{"role":"aut","family":"Hückelhoven-Krauss","given":"Angela","display":"Hückelhoven-Krauss, Angela"},{"role":"aut","given":"Christian","display":"Kleist, Christian","family":"Kleist"},{"display":"Eckstein, Volker","given":"Volker","family":"Eckstein","role":"aut"},{"family":"Sellner","display":"Sellner, Leopold","given":"Leopold","role":"aut"},{"family":"Müller-Tidow","display":"Müller-Tidow, Carsten","given":"Carsten","role":"aut"},{"role":"aut","display":"Dreger, Peter","given":"Peter","family":"Dreger"},{"family":"Schmitt","given":"Michael","display":"Schmitt, Michael","role":"aut"},{"role":"aut","given":"Anita","display":"Schmitt, Anita","family":"Schmitt"}],"recId":"1761975218","name":{"displayForm":["Mingya Yang, Lei Wang, Ming Ni, Brigitte Neuber, Sanmei Wang, Wenjie Gong, Tim Sauer, Maria-Luisa Schubert, Angela Hückelhoven-Krauss, Ruixiang Xia, Jian Ge, Christian Kleist, Volker Eckstein, Leopold Sellner, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt and Anita Schmitt"]},"origin":[{"dateIssuedDisp":"26 May 2021","dateIssuedKey":"2021"}],"relHost":[{"origin":[{"publisher":"Frontiers Media","dateIssuedDisp":"2010-","dateIssuedKey":"2010","publisherPlace":"Lausanne"}],"title":[{"title_sort":"Frontiers in immunology","title":"Frontiers in immunology"}],"id":{"eki":["657998354"],"zdb":["2606827-8"],"issn":["1664-3224"]},"part":{"text":"12(2021) vom: 26. Mai, Artikel-ID 670088","volume":"12","year":"2021","extent":"13"},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 07.11.13"],"disp":"Dual effects of cyclooxygenase inhibitors in combination with CD19.CAR-T cell immunotherapyFrontiers in immunology","recId":"657998354","language":["eng"],"pubHistory":["1.2010 -"],"type":{"media":"Online-Ressource","bibl":"periodical"}}],"note":["Gesehen am 06.07.2021"],"physDesc":[{"extent":"13 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["1761975218"],"doi":["10.3389/fimmu.2021.670088"]}} | ||
| SRT | |a YANGMINGYADUALEFFECT2620 | ||